Moving Medicare Coverage
Executive Q&A: How shifting coverage for some drugs from Medicare Part B to Part D could impact access and affordability for patients.
Medicare Part B: Do Providers Choose Treatment Based on Payment?
What does Medicare claims data reveal about physician-administered drugs? An Xcenda survey reveals whether physicians choose treatment based on how much they're reimbursed.
Preparing Patients for Open Enrollment
Open enrollment for Health Insurance Marketplace plans is here. Do PAP patients know their coverage options?
How Policy Impacts Patient Support
What role does the changing healthcare coverage landscape play in support program demand and design?
How to Navigate Cell and Gene Therapy Reimbursement: Part Two
An executive Q&A on the role of data and the future of innovative reimbursement modeling for cell and gene therapies.
How to Navigate Cell and Gene Therapy Reimbursement: Part One
An executive Q&A on challenges and opportunities related to reimbursement, coding and coverage for cell and gene therapies.
Our Look at "American Patients First"
Our experts look at what President Trump's new plan for reducing drug prices means for manufacturers, pharmacies and the drug wholesale industry.
2018 Healthcare Outlook
Key healthcare and health policy trends to watch in 2018 -- and what they mean for pharmaceutical manufacturers.
Eight Impact Making Advocacy Tips for Pharmacists
Political advocacy can be intimidating, but it doesn’t need to be. Here are a few tips to help you get started.
Alternative methodologies for coding biosimilars reveal an addition $15.1 billion in hidden savings.
Take a Stand Against DIR Fees
How pharmacies can take action now.
Understanding Barriers to Adopting Precision Medicine
Precision medicine can improve patient outcomes and increase the effectiveness of therapy but physicians must still carefully navigate certain barriers.